Article Data

  • Views 595
  • Dowloads 119

Original Research

Open Access

Has the “paradigm shift” in the management of advanced ovarian, tubal and primary peritoneal cancer altered the locations of recurrence?

  • A. Phillips1,*,
  • S. Sundar1
  • R. Pounds1
  • A. Elattar1
  • J. Nevin1
  • S. Kehoe1
  • J. Balega1
  • K. Singh1

1Pan-Birmingham Gynaecological Cancer Centre, City Hospital, Birmingham, United Kingdom

DOI: 10.12892/ejgo4183.2018 Vol.39,Issue 3,June 2018 pp.365-371

Published: 10 June 2018

*Corresponding Author(s): A. Phillips E-mail: drandyphillips@gmail.com

Abstract

Purpose of investigation: To determine the pattern of disease recurrence in patients treated for advanced ovarian cancer (AOC). Materials and Methods:A retrospective review of the locations of recurrence in all patients treated for AOC between August 16, 2007 and February 3, 2014 who underwent cytoreductive surgery and platinum based chemotherapy achieving complete (R0) or optimal (< 1cm) (R1) cytoreduction. Results: The study identified 254 patients. Peritoneal site relapses affected 65.4–91.1% of patients and were more common in R1 compared to R0 patients (p = 0.01891). Ascites at relapse was less prevalent in R0 compared to R1 patients (p = 0.00185) and occurred less with more complex surgery (p = 0.00497) and 19.2% of patients who required high complexity surgery to achieve R0 only experienced retroperitoneal recurrences. Conclusion: Irrespective of the surgery undertaken, the peritoneum is the commonest site of recurrence. The surgical complexity required to achieve R0 seemingly alters the relapse pattern by reducing ascites and peritoneal relapse compared to those with R1 disease, and increasing retroperitoneal relapse.

Keywords

Ovarian cancer; Fallopian tube cancer; Peritoneal neoplasms; Recurrence; Surgery.

Cite and Share

A. Phillips,S. Sundar,R. Pounds,A. Elattar,J. Nevin,S. Kehoe,J. Balega,K. Singh. Has the “paradigm shift” in the management of advanced ovarian, tubal and primary peritoneal cancer altered the locations of recurrence?. European Journal of Gynaecological Oncology. 2018. 39(3);365-371.

References

[1] Eisenkop S.M., Friedman R.L., Wang H.J.: “Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study”. Gyneco.l Oncol., 1998, 69, 103.

[2] Chi D.S., Eisenhauer E.L., Zivanovic O., Sonoda Y., Abu-Rustum N.R., Levine D.A., et al.: “Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm”. Gynecol. Oncol., 2009, 114, 26.

[3] Colombo P.E., Mourregot A., Fabbro M., Gutowski M., Saint-Aubert B., Quenet F., et al.: “Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients”. Eur. J. Surg. Oncol., 2009, 35, 135.

[4] Horowitz N.S., Miller A., Rungruang B., Richard S.D., Rodriguez N., Bookman M.A., et al.: “Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182”. J. Clin. Oncol., 2015, 33, 937.

[5] Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al.: “Aggressive surgical effort and improved survival in advanced-stage ovarian cancer”. Obstet. Gynecol., 2006, 107, 77.

[6] Wright A.A., Bohlke K., Armstrong D.K., Bookman M.A., Cliby W.A., Coleman R.L., et al.: “Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline”. J. Clin. Oncol., 2016, 34, 3460.

[7] DESKTOP III. DESKTOP III 2015 [cited 2015 22 Jan]. Available at: http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID=11498

[8] CHIPOR. CHIPOR [cited 2016 5 June]. Available at: https://clinicaltrials.gov/show/NCT01376752.

[9] SOR-1. SOR-1 [cited 2016 6 June]. Available at: https://clinicaltrials.gov/ct2/show/NCT01611766?term=ovarian+recurrent&recr=Open&rank=18.

[10] Cancer HICfRO. Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer [cited 2016 6 June]. Available at: https://clinicaltrials.gov/ct2/show/NCT02672098?term=ovarian+recurrent&recr=Open&rank=52.

[11] Aletti G.D., Eisenhauer E.L., Santillan A., Axtell A., Aletti G., Holschneider C., et al.: “Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment”. Gynecol. Oncol., 2011, 120, 23.

[12] Rustin G.J., Vergote I., Eisenhauer E., Pujade-Lauraine E., Quinn M., Thigpen T., et al.: “Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)”. Int. J. Gynecol. Cancer, 2011, 21, 419.

[13] Amate P., Huchon C., Dessapt A.L., Bensaid C., Medioni J., Le Frere Belda M.A., et al.: “Ovarian cancer: sites of recurrence”. Int. J. Gynecol. Cancer, 2013, 23, 1590.

[14] Esselen K.M., Rodriguez N., Growdon W., Krasner C., Horowitz N.S., Campos S.: “Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy”. Gynecol. Oncol., 2012, 127, 51.

[15] Rodriguez N., Miller A., Richard S.D., Rungruang B., Hamilton C.A., Bookman M.A., et al.: “Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182”. Gynecol. Oncol., 2013, 130, 487.

[16] SOCQER-2. SOCQER-2 2016 [cited 2016 7th June]. Available at: https://clinicaltrials.gov/ct2/show/NCT02569983.

[17] Harter P., Sehouli J., Reuss A., Hasenburg A., Scambia G., Cibula D., et al.: “Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO”. Int. J. Gynecol. Cancer, 2011, 21, 289.

[18] Petrillo M., Ferrandina G., Fagotti A., Vizzielli G., Margariti P.A., Pedone A.L., et al.: “Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy”. Ann. Surg. Oncol., 2013, 20, 3955.

[19] Vergote I., Trope C.G., Amant F., Kristensen G.B., Ehlen T., Johnson N., et al.: “Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer”. N. Engl. J. Med., 2010, 363, 943.

[20] Kehoe S., Hook J., Nankivell M., Jayson G.C., Kitchener H., Lopes T., et al.: “Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial”. Lancet, 2015, 386, 249.

[21] Jacquet P., Jelinek J.S., Steves M.A., Sugarbaker P.H.: “Evaluation of computed tomography in patients with peritoneal carcinomatosis”.

Cancer, 1993, 72, 1631.

[22] de Bree E., Koops W., Kroger R., van Ruth S., Witkamp A.J., Zoetmulder

F.A.: “Peritoneal carcinomatosis from colorectal or appendiceal

origin: correlation of preoperative CT with intraoperative

findings and evaluation of interobserver agreement”. J. Surg. Oncol.,

2004, 86, 64.

[23] Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A.,

Raman S., et al.: “Multi-institutional reciprocal validation study of

computed tomography predictors of suboptimal primary cytoreduction

in patients with advanced ovarian cancer”. J. Clin. Oncol., 2007,

25, 384.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top